Navigation Links
Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201

-tolerated at both doses without any serious adverse events.

Further analysis of the remaining secondary endpoints is ongoing.

Jorn Aldag, President and Chief Executive Officer, Evotec AG, said: "We are very pleased with the positive outcome of this clinical trial. Our first drug with proof-of-concept in patients is a major milestone in Evotec's transition into a CNS focused biopharmaceutical company."

Commenting on the results, Dr John Kemp, Chief Research & Development Officer, Evotec AG, added: "We have always considered that EVT 201 has the potential to help patients to fall asleep quickly, help them stay asleep during the night and allow them to awake in the morning feeling refreshed and without any hang-over effect. It thereby meets the major needs of insomniac patients without the need for a sustained release formulation. These results confirm that potential in the primary patient population."

Dr Tim Tasker, Executive Vice President Clinical Development, Evotec AG, added: "The results provide our first evidence that this partial agonist is effective in patients. The profile shows large effects on sleep onset and maintenance without any subjective evidence of hang-over the next day."

Principal Investigator Dr James Walsh, Executive Director of the Sleep Medicine and Research Center, St John's Mercy Medical Center, Chesterfield, Missouri, US, said: "This first study of EVT 201 in patients provided highly significant and robust effects upon polysomnographically measured sleep for both doses. In addition patients reported an improved quality of sleep. Ratings of alertness in the morning were not impaired and findings on DSST were quite small. These are encouraging results which offer significant promise for the drug as a treatment for insomnia patients."

A second Phase II clinical trial of EVT 201 in elderly patients with chronic insomnia for further differentiation is ongoing. Top-line results from this trial are exp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
(Date:8/1/2014)... 2014 MGC Diagnostics Corporation (NasdaqCM: MGCD), ... that it has completed its acquisition of MediSoft ... products based in Sorinnes, Belgium ... cardiorespiratory diagnostics market since 1977. MediSoft, a calendar ... million ($6.3 million) and incurred a net loss ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
(Date:8/1/2014)... In a first-of-its-kind study, researchers at University Hospitals Rainbow ... infants may be at greater risk for death on ... emergencies on flights worldwide between January 2010 and June ... children under the age of 2. , The ... the rare event of an in-flight pediatric fatality onboard ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... fears, emotions and the benefits of a cancer diagnosis ... according to a study conducted by a researcher at ... to developing an expressive writing intervention is the writing ... facts and events. Writing a journal can be therapeutic, ... determine whether it,s effective or not," said Qian Lu, ...
(Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
... against blood loss, study finds , , THURSDAY, Sept. 27 ... the rescue of trauma victims suffering from heavy blood ... , "This is the first scientific study showing the ... author Dr. Marie-Pierre Poloujadoff, an emergency physician at one ...
... Mich., Sept. 27 Stryker,Corporation (NYSE: SYK ... resolution,with the United States Attorney,s office in Newark, ... practices in the,orthopaedic industry. The investigation began with ... 2005 that requested documents for the,period January 2002 ...
... Consumers Measure Their ... Wellness Habits, ... campaign set out to determine if we are a,nation of AlphaWells, ... -- http://www.lifesupplemented.org -- which includes the free,interactive tool My ...
... The Patient,Advocate Foundation (PAF) -- a national non-profit ... of patients every year who,are unable to obtain ... --announced this month the addition of four new ... medical professionals ---,Roy Ramthun; Pearl Moore, RN; Alan ...
... gene-based screens , , THURSDAY, Sept. 27 (HealthDay News) -- ... genetic tests that predict which patients will have adverse ... nonprofit organization dubbed the International Serious Adverse Events Consortium ... drug-related liver toxicity and the other aimed at a ...
... -- Workshops, online programs and databases are just some ... about the biosciences, food safety and animal health with ... food supply. , In the past 27 years, more ... around the world have turned to Kansas State University ...
Cached Medicine News:Health News:Toxic Shock Drug Might Aid Trauma Victims 2Health News:Toxic Shock Drug Might Aid Trauma Victims 3Health News:Stryker Announces Resolution Related to March 2005 U.S. Department of Justice Subpoena 2Health News:Are You An AlphaWell or An OhWell? 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 3Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 2Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 3Health News:Professionals in bioscience, food-related industries turn to K-State 2Health News:Professionals in bioscience, food-related industries turn to K-State 3
... Antigen (PSA) derives its name from its ... gland. The majority of PSA circulates ... Serum concentrations of PSA are elevated ... hypertrophy (BPH) and prostatitis [1-3]. In addition, ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Medicine Products: